The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.
about
Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individualsImpact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials*Gender difference in 2-year mortality and immunological response to ART in an HIV-infected Chinese population, 2006-2008Asking the right questions: developing evidence-based strategies for treating HIV in women and childrenAdverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medicationPhysical and emotional health outcomes after 12 months of public-sector antiretroviral treatment in the Free State Province of South Africa: a longitudinal study using structural equation modelling.Who is accessing public-sector anti-retroviral treatment in the Free State, South Africa? An exploratory study of the first three years of programme implementationA higher correlation of HCV core antigen with CD4+ T cell counts compared with HCV RNA in HCV/HIV-1 coinfected patientsThe relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa.High Rate of Non-detectable HIV-1 RNA Among Antiretroviral Drug Naive HIV Positive Individuals in NigeriaOutcomes of second-line combination antiretroviral therapy for HIV-infected patients: a cohort study from Rio de Janeiro, Brazil.The Expanding Class of Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV-1 InfectionIncidence and determinants of nevirapine and efavirenz-related skin rashes in West Africans: nevirapine's epitaph?Predictors of disease progression in HIV infection: a review.Efavirenz conceptions and regimen management in a prospective cohort of women on antiretroviral therapy.The nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in the treatment of HIV.Combining Non-randomized and Randomized Data in Clinical Trials Using Commensurate PriorsEfficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).Universal testing and treatment as an HIV prevention strategy: research questions and methods.British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).Neuropsychiatric side effects of efavirenz therapy.Toxicity-related antiretroviral drug treatment modifications in individuals starting therapy: a cohort analysis of time patterns, sex, and other risk factors.Short-term treatment outcomes in human immunodeficiency virus type-1 and hepatitis B virus co-infectionsA feasibility study of immediate versus deferred antiretroviral therapy in children with HIV infectionTwenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA)DRESS Syndrome due to Nevirapine Treated with MethylprednisoloneSupersensitive Viral Load Assay in Predicting CD4-Guided Treatment Failure.A model and risk score for predicting nevirapine-associated rash among HIV-infected patients: in settings of low CD4 cell counts and resource limitationHLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients.Gender differences in discontinuation of antiretroviral treatment regimens.HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play?Modelling the evolution of HIV-1 virulence in response to imperfect therapy and prophylaxisChanges to antiretroviral drug regimens during integrated TB-HIV treatment: results of the SAPiT trialIncidence and Predictors of Antiretroviral Treatment Modification in HIV-Infected Adults: A Brazilian Historical Cohort from 2001 to 2010.Effect of therapy switch on time to second-line antiretroviral treatment failure in HIV-infected patients.Severe antiretroviral-associated skin reactions in South African patients: a case series and case-control analysis.Sex-specific differences in treatment outcomes for patients with HIV and AIDS.Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequences.Factors associated with poor CD4 and viral load outcomes in patients with HIV/AIDS.Low-frequency NNRTI-resistant HIV-1 variants and relationship to mutational load in antiretroviral-naïve subjects.
P2860
Q24235724-D88C8122-D625-4A2E-8447-EB9AFD2348FEQ27015850-EB04E8CC-DCE1-4B3D-BAE6-0E04D32AD790Q28741389-1BBA6944-A0AE-4D5C-88E5-B61332D940F9Q28743488-375AE5A1-BEEF-4193-B3BF-CEA40F7C94CCQ28749406-7672290E-E2E8-4E19-A807-A69977E198AFQ33430504-9545B3FC-2A53-4324-BAC5-928F6E7A5080Q33622913-157C58A3-B527-4DF3-AF25-4B6E6E6B83A9Q33999798-8FCA3E8E-D356-4658-9E91-671469EDEE5CQ34433397-7B8716E7-8FE6-494D-B101-F9E53C88DE57Q34463096-9E4D21AC-1B8E-4A04-89B2-73E5135298BEQ34979072-75A1AEA1-5684-4451-86D2-7FDAD5696A41Q35111300-CD361F04-8C98-4FD9-B60C-D14B4F6E2AD9Q35146943-0916E711-287A-415F-B7A1-A70599053746Q35834337-BB48E034-47C8-4F74-BDE9-777582B9AD58Q36063532-C6321A10-19AD-44E6-8318-F3A83C7E4183Q36271415-B2E43AC6-FC15-4F2C-A7B9-633C55507489Q36359341-773F2936-2E9F-47FA-9ED1-AC9B9F276958Q36447469-72D5DFBA-7800-4AE3-A323-BB4833FEC7BDQ36460647-FFC97E48-2DD4-40FE-9BD1-459E0A361FA9Q36653838-47E8060D-4325-469F-A9ED-DB0319A9C373Q36762436-491D4C10-0829-429E-BF85-0170E4F26595Q36954711-5F52A0DA-C6FD-4894-A7CB-1A0608B2309EQ36960592-0400AC8F-9505-43C9-B719-5EF10092AA2FQ36975397-68EDC6D7-7E84-4374-8DFC-202BC4B9176DQ37082924-09FA4655-8084-407C-9BE2-A64E3F31190CQ37105065-79874A89-0D64-45D9-99B7-9A0481614152Q37183617-71151D38-4B7E-4FE9-8D95-70DC8F7F8EFEQ37271902-E0EAA6B0-0551-4037-BAEB-3877E9CEF1B2Q37414313-70843D25-75BA-4F91-9CB3-0654558855A4Q37440855-2B132A99-D534-4168-A2BC-3C07B2F2223AQ37644125-9F3FAD54-3E9E-4F4A-8B9A-51633920AF42Q37661125-5E38C5F5-0879-4A75-B2CF-AA44ED6C764CQ37699575-D4D329D0-0EEC-4522-9CBD-50DE51726547Q37699865-AEF9F723-52AF-488B-98C3-84C545CAC4F1Q38669988-D69B4FFC-BA25-4B11-B13A-D5A12EB50672Q39553824-362D82CC-2940-473B-BFBE-300D6A923D5DQ40129396-202F3E5A-1D0C-4F98-99A5-B83A294A30F1Q40404531-9406A1B2-A0CD-4BD9-94DB-F72A27ECC568Q40509436-02DF4106-6A74-4E6E-9645-61A14258FA52Q41726095-8D057C97-9487-4882-A726-2D2E6ADE8D8B
P2860
The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
The effect of baseline CD4 cel ...... virenz-based first-line HAART.
@ast
The effect of baseline CD4 cel ...... virenz-based first-line HAART.
@en
The effect of baseline CD4 cel ...... virenz-based first-line HAART.
@nl
type
label
The effect of baseline CD4 cel ...... virenz-based first-line HAART.
@ast
The effect of baseline CD4 cel ...... virenz-based first-line HAART.
@en
The effect of baseline CD4 cel ...... virenz-based first-line HAART.
@nl
prefLabel
The effect of baseline CD4 cel ...... virenz-based first-line HAART.
@ast
The effect of baseline CD4 cel ...... virenz-based first-line HAART.
@en
The effect of baseline CD4 cel ...... virenz-based first-line HAART.
@nl
P2093
P1433
P1476
The effect of baseline CD4 cel ...... virenz-based first-line HAART.
@en
P2093
2NN study group
B Grinsztejn
F van Leth
J M A Lange
J Montaner
M K Lazanas
P304
P356
10.1097/01.AIDS.0000162334.12815.5B
P407
P577
2005-03-01T00:00:00Z